SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VOR

Vor Biopharma Inc. (NASDAQ:VOR)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$19.19+$0.67 (+3.62%)
 
Market cap
$1.04B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 5, 2021
Website
Market Cap$1.04B+157.6%
Revenue (ttm)$0
Net Income$1.35B+155.3%
EPS$36.78+109.5%
Shares Out54.19M
PE Ratio0.06
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,554,050
Open$18.52
Previous Close$18.52
Day's Range$18.52 - $19.90
52-Week Range$7.21 - $26.00
Beta1.83
AnalystsBuy
Price Target$33.50(+74.57%)
Earnings DateMar 29, 2027

About VOR

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Address
500 Boylston Street, Boston, MA, 02116, US
Market Cap
1.04 billion
Employees
76
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$65.99M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From VOR’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+3.62%
5 Days
+0.95%
1 Month
+1.32%
6 Months
+27.59%
1 Year
+157.58%

$VOR stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VOR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VOR's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VOR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New VOR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VOR from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VOR

VTIVanguard Morningstar Total Stock Market ETF$24.06M
XBIState Street SPDR S&P Biotech ETF$20.72M
IWMiShares Russell 2000 ETF$18.51M
VXFVanguard Extended Market ETF$8.62M
FESMFidelity Enhanced Small Cap ETF$4.92M
IWOiShares Russell 2000 Growth ETF$4.63M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VOR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Strategic partnership expansion with RemeGen adding promising pipeline asset RC298; narrowing losses suggest improving financial trajectory.

Recent Insider Activity

Buys
0
Sells
23
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF1.03%
SBIOALPS Medical Breakthroughs ETF0.75%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.36%
XBIState Street SPDR S&P Biotech ETF0.21%
OMFSInvesco Russell 2000 Dynamic Multifactor ETF0.21%
IWCiShares Micro-Cap ETF0.19%
FSCCFederated Hermes MDT Small Cap Core ETF0.18%
FFSMFidelity Fundamental Small-Mid Cap ETF0.16%
FSMOFidelity Fundamental Small-Mid Cap ETF0.16%
OPTZOptimize Strategy Index ETF0.14%
ACSGAmerican Century Small Cap Growth Insights ETF0.11%
FSEGFidelity Enhanced Small Cap Growth ETF0.09%

Weight is the stock’s share of each fund’s holdings.